Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by LAU, C. S.
Right arrow Articles by BELCH, J. J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LAU, C. S.
Right arrow Articles by BELCH, J. J. F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1991 British Society for Rheumatology


research-article

FACTOR VIII VON WILLEBRAND FACTOR ANTIGEN LEVELS CORRELATE WITH SYMPTOM SEVERITY IN PATIENTS WITH RAYNAUD'S PHENOMENON

C. S. LAU, M. MCLAREN and J. J. F. BELCH

University Department of Medicine, Ninewells Hospital and Medical School Dundee DD1 9SY, Scotland

Correspondence to: Correspondence to Dr C. S. Lau

We have previously documented raised levels of factor VIII von Willebrand factor antigen (FVIII vWF Ag), an endothelial product, in patients with vascular diseases and suggested that levels of this relate to disease activity. No one has yet investigated patients with Raynaud's phenomenon (RP) alone to see if the severity of vasospastic attacks relates to FVIII vWF Ag.

We studied 22 patients with RP. None of these patients fulfilled diagnostic criteria for a connective tissue disease but all had severe symptoms which warranted referral to hospital. We measured the FVIII vWF Ag and the procoagulant factor VIII (FV1II:c) levels in these patients. FV1II:c is not an endothelial product and is released by different mechanisms, thus it forms an active control to FVIII vWF Ag. FVIII vWF Ag measurements were carried out using the Laurel1 method and FVII1:c was assessed using the technique described by Nilsson. Patients were asked to complete diaries over a 2-week winter period. The frequency and duration of all Raynaud's attacks were recorded. There were significant positive correlations between FVIII vWF Ag and the total number and duration of RP attacks over the 2-week period (P<0.005, r=0.67 and P<0.05, r=0.40, respectively; Spearman's rank correlation). No correlation was found between levels of FVII1:c and the same clinical parameters.

It has been suggested that patients with clinical evidence of vascular damage have elevated plasma levels of FVIII vWF Ag. Our present study has demonstrated correlations between FVIII vWF Ag levels and the clinical severity of vasospasm in patients with RP. Whether severe blood vessel spasm causes an increase in FVIII vWF Ag release or patients with blood vessel damage have more severe attacks of RP is not yet clear; however, FVIII vWF Ag levels may serve as a marker of disease activity in these patients.

KEY WORDS: Vasospasm, Endothelium, Endothelial damage


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Rheumatology (Oxford)Home page
V. Young, M. Ho, H. Vosper, J. J. F. Belch, and C. N. A. Palmer
Elevated expression of the genes encoding TNF-{alpha} and thromboxane synthase in leucocytes from patients with systemic sclerosis
Rheumatology, August 1, 2002; 41(8): 869 - 875.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
M. Ho, D. Veale, C. Eastmond, G. Nuki, and J. Belch
Macrovascular disease and systemic sclerosis
Ann Rheum Dis, January 1, 2000; 59(1): 39 - 43.
[Abstract] [Full Text]


Home page
CLIN APPL THROMB HEMOSTHome page
M. McLaren, T. A. Elhadd, S. A. Greene, and J. J. J. F. Belch
Elevated Plasma Vascular Endothelial Cell Growth Factor and Thrombomodulin in Juvenile Diabetic Patients
Clinical and Applied Thrombosis/Hemostasis, January 1, 1999; 5(1): 21 - 24.
[Abstract] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.